Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosis

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 1, 2014, Pages 64-72

  Xiao, Junfeng ^a   Zhao, Yi ^a   Varghese, Rency S ^a   Zhou, Bin ^a   Di Poto, Cristina ^a   Zhang, Lihua ^a   Tadesse, Mahlet G ^b   Ziada, Dina Hazem ^d   Shetty, Kirti ^c   Ressom, Habtom W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AMINO ACID; BILE ACID; BIOLOGICAL MARKER; CARNITINE; SPHINGOLIPID;

ADULT; AFRICAN AMERICAN; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EGYPT; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; METABOLITE; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SEROLOGY; SERUM; SEX DIFFERENCE; STANDARD; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892747453     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0327     Document Type: Article

References (31)

1. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002;963: 13-20.
2. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000;14:703-9.
3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the united states. Hepatology 2002;36:s74-83.
4. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the united states. Am J Public Health 2000;90:1562-9.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365: 1118-27.
6. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-8.
7. Poustchi H, Ghajarieh Sepanlou S, Esmaeili S, Mehrabi M, Ansarymoghadam A. Hepatocellular carcinoma in the world and the middle east. Middle East J Dig Dis. 2011;2:31-41.
8. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the united states from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
9. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005;41:634-42.
10. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
11. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011;10:M110.004945.
12. Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol 2004;5:763-9.
13. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem 2007;363:185-95.
14. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2003;2:668-76.
15. Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in egyptian cohort. J Proteome Res 2012;11:5914-23.
16. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012;743:90-100.
17. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011;71: 6590-600.
18. Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics 2012;11:M111.010694.
19. Yang J, Zhao X, Liu X, Wang C, Gao P, Wang J, et al. High performance liquid chromatography mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J Proteome Res 2006;5:554-61.
20. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009;5:868-76.
21. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-6.
22. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
23. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science 2007;317:121-4.
24. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993;53:790-4.
25. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitisCvirus cirrhosis. Hepatology 2002;36: 410-7.
26. Li S, Liu H, Jin Y, Lin S, Cai Z, Jiang Y. Metabolomics study of alcoholinduced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2369-75.
27. Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, et al. Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virusrelated cirrhosis. Cancer Epidemiol Biomarkers Prev 2011;20: 1439-46.
28. Lee HS, Chung YH, Kim CY. Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg+ patients in the diagnosis of hepatocellular carcinoma. Hepatology 1991;14:68-72.
29. Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012;11:1217-27.
30. Goto T, Myint KT, Sato K, Wada O, Kakiyama G, Iida T, et al. LC/ESItandem mass spectrometric determination of bile acid 3-sulfates in human urine 3beta-sulfooxy-12alpha-hydroxy-5beta-cholanoic acid is an abundant nonamidated sulfate. J Chromatogr B Analyt Technol Biomed Life Sci 2007;846:69-77.
31. Gowda GA. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark Med 2010;4:299-314.